The druggable genome

By A. Hopkins, Colin R. Groom. Nature reviews. Drug discovery, 2002

3,254 citations recorded by the source corpus.

View Paper: https://www.semanticscholar.org/paper/648a2ef46c4f7b335741111c445ee26adf2f0644

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Structure-Based Virtual Screening for Drug Discovery: a Problem-Centric Review (2012, background): “The completion of the Human Genome Project has revealed a wealth of attractive druggable targets (3).”
Proteolysis Targeting Chimeras as Therapeutics and Tools for Biological Discovery (2020, neutral): “, 2018), only 10–15% are considered druggable (Hopkins and Groom, 2002) but many more have been shown to be ligandable (Backus et al.”
Rethinking Protein Drug Design with Highly Accurate Structure Prediction of Anti-CRISPR Proteins (2021, background): “Thus, modern medicine has focused on targeting such proteins to alleviate diseases, mostly through small-molecule therapeutic agents acting as competitive or non-competitive inhibitors [3].”
Multipass membrane protein structure prediction using Rosetta (2005, neutral): “The biological significance of the helical TM proteins is highlighted by the fact that 50% of current drugs in use target membrane proteins.(1) Helical TM proteins are predicted to encode 20–30% of all open reading frames of known genomes; however, currently, all types of membrane proteins represent”
Whole genome sequencing resource identifies 18 new candidate genes for autism spectrum disorder (2017, neutral): “The PFAM labels were compared to lists of protein families generally considered to be druggable 70,71 .”
Global mapping of pharmacological space (2006, background): “Because of the lack of integrated knowledge bases in pharmaceutical research, the list of molecular targets for which small-molecule chemical matter has been discovered has been difficult to ascertai”
Human and mouse proteases: a comparative genomic approach (2003, background): “From the clinical point of view, the availability of a complete protease catalogue will facilitate the identification of protease genes that are responsible for genetic diseases that are associated with protease deficiencies, and the evaluation of new proteases as drug targets or prognostic marker”
Virtual ligand screening: strategies, perspectives and limitations (2006, background): “If one member of such a family is able to bind a drug, other members might also be able to bind druglike ligands with related physicochemical properties [34] .”
Ligand–receptor interaction platforms and their applications for drug discovery (2012, background): “Our improved understanding of the molecular basis of human diseases has expanded the list of targets used for developing new therapeutics [1,2].”
Localized Surface Plasmon Resonance Biosensing: Current Challenges and Approaches (2015, background): “In particular, G protein-coupled receptors have emerged as predominant targets for pharmaceutical therapies [105,106].”
Drugs, their targets and the nature and number of drug targets (2006, background): “And on the basis of ligand-binding studies, 399 molecular targets were identified belonging to 130 protein families, and ∼3,000 targets for small-molecule drugs were predicted to exist by extrapolations from the number of currently identified such targets in the human genom”
Chemical space and biology (2004, background): “So far, analyses have revealed that the total number of human proteins against which drugs have been targeted is less than 500 (ref”